** U.S.-listed shares of cancer drug developer BeiGene 688235.SS, ONC.O fall 3.2% to $266.03
** Co says it is discontinuing development of its experimental lung cancer drug, ociperlimab, in a late-stage trial
** Independent data monitoring committee recommended terminating the trial
** Study unlikely to meet the main goal of improving overall survival, co says
** As of last close, ONC up ~49% YTD vs. 2.4% decline in the Nasdaq biotechnology index .NBI
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。